Q-omics provides the consensus-scored TRIM60P17 profile across patient tissues and cancer cell-line models. TRIM60P17 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRIM60P17 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, TRIM60P17 RNA expression shows 13,538 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where TRIM60P17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM60P17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM60P17 survival associations across molecular data types. TRIM60P17 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM60P17 RNA expression–survival associations across cancer types. High TRIM60P17 expression shows unfavorable associations in HNSC, READ and LIHC, but favorable associations in LUAD, UVM and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify HNSC as the clearest survival context for TRIM60P17 RNA expression.
This table summarizes TRIM60P17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM60P17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM60P17 shows lower tumor expression in COAD, KICH, UCEC, BRCA, LUAD and LUSC. The COAD box plot shows higher TRIM60P17 RNA expression in normal versus tumor tissue (log2 FC = −0.222, t-test p < 0.001).
This table shows molecular features associated with TRIM60P17 in patient tissues and cancer cell lines. In patient samples, TRIM60P17 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
